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Introduction: the goals of antimicrobial therapy 
Jae-Hoon Song(i) 
Antimicrobial agents are generally evaluated in preclinical studies assessing in vitro activity, animal models demon- 
strating in vivo bacteriologic efficacy, and clinical trials primarily investigating safety and clinical efficacy. However, 
large sample sizes are required to detect any differences in outcomes between antimicrobials in clinical trials, and, 
generally, studies are powered to show only clinical equivalence. In addition, diagnosis is often based on clinical 
symptoms, rather than microbiological evidence of bacterial infection, and the patients most likely to have resistant 
pathogens are often excluded. Clinical efficacy can be achieved in some bacterial infections in which antimicrobials 
are suboptimal or even not prescribed. However, bacterial eradication maximizes clinical efficacy and may also 
reduce the development and spread of resistant organisms. The goal of antimicrobial therapy is, therefore, to 
eradicate bacteria at the site of infection. Bacterial eradication is not usually assessed as a primary endpoint within 
the limits of currently recommended clinical trial design. However, pharmacokinetic (PK) (serum concentration 
profiles, penetration to site of infection) and pharmacodynamic (PD) (susceptibility, concentration- versus time- 
dependent killing, post-antimicrobial effects) criteria can be used to predict bacteriologic efficacy. PK/PD predictions 
should be confirmed during all phases of antimicrobial development and throughout clinical use in response to 
changing patterns of resistance. A clear rationale for dose recommendations can be determined preclinically based 
on PK/PD parameters, and correlated with efficacy, safety and resistance endpoints in clinical trials. The duration of 
treatment and dose should be the shortest that will reliably eradicate the pathogen(s), and that is safe and well 
tolerated. Currently available agents vary significantly in their ability to achieve PK/PD parameters necessary for 
bacteriologic eradication. Recommendations for appropriate antimicrobial therapy should be based on PK/PD 
parameters, with the aim of achieving the maximum potential for eradication of both existing and emerging resistant 
pathogens. 
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INTRODUCTION 
Infectious disease remains a major cause of death and 
morbidity. According to data from the World Health 
Organization (WHO) in 1998, infection was the second 
most common cause of death, causing 25% of deaths 
wor1dwide.l However, in developing countries, infectious 
diseases accounted for almost half of all deaths. 
Importantly, infection was responsible for more than 
60% of all deaths among children aged O-4 years. The 
WHO data also show that almost 90% of deaths from 
infectious diseases were caused by six major diseases, of 
which acute respiratory tract infection was the main 
contributor (Figure l).l 
Although the development of antimicrobials has 
greatly reduced mortality and morbidity from infectious 
diseases, at least in the developed world, the emergence 
of resistance to antimicrobials threatens to undermine 
these advances. In particular, the global emergence of 
bacterial resistance in respiratory tract infections is 
of considerable concern. All of the major bacterial 
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pathogens involved in these infections, Streptococcus 
pneumoniae, Haemophilus injluenzae, and Movaxella 
cataruhalis, have developed resistance to one or more 
antimicrobial classes. For example, S. pneumoniae has 
developed resistance to all classes of antimicrobial agent 
used to treat respiratory tract infections, although 
resistance prevalences vary between regions and for 
different antimicrobial agents. 
The history of antimicrobial use in respiratory tract 
infection and the emergence of resistance indicates that 
there are still serious problems in defining and choosing 
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Figure 1. Leading causes of mortality due to infectious 
diseases. Redrawn with permission from the WHO.’ 
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the best (most appropriate) antimicrobials for clinical 
therapy. In order to achieve successful therapy of respira- 
tory tract infection, we need to define clear goals for 
‘success’, and an evidence-based approach for deter- 
mining the potential of different therapies to achieve 
these goals. This supplement outlines the importance of 
bacterial eradication as the primary goal of antimicrobial 
therapy (see J. Garau, this issue). Pharmacokinetic (PK) 
and pharmacodynamic (PD) analyses can be used 
to predict bacterial eradication and applied to the 
assessment and choice of agents currently used for the 
treatment of respiratory tract infections as well as 
the development of improved formulations and new 
antimicrobials (see M. R. Jacobs and R. Dagan, this 
issue). Finally, the need for changes in prescribing 
practice, driven by PK/PD predictions of bacterial 
eradication to maximize clinical outcomes and minimize 
the emergence and spread of resistance, is examined 
(see K. Klugman, this issue). 
APPROPRIATE PRESCRIBING AND 
DRUG DEVELOPMENT 
The continued development and spread of antimicrobial- 
resistant bacterial strains creates an urgent need for the 
development of new antimicrobials and the appropriate 
use of currently available agents. Few new antimicrobials 
are now reaching the market; development timelines are 
lengthy, often more than a decade, and new agents are 
untried in clinical practice. There are many examples 
showing that the safety profile of a new agent cannot be 
guaranteed based on the profiles of other antimicrobials 
in the same class. In addition, for new agents developed 
from existing antimicrobial classes, cross-resistance with 
other members of the class may also be a problem. The 
continued development of currently available agents 
through the introduction of new formulations and 
doses is attractive, as it is likely to be much faster than 
developing new antimicrobials, and has the advantage 
of a known efficacy and safety record. However, new 
formulations/doses must be able to overcome existing 
bacterial resistance. 
LIMITATIONS OF CLINICAL ASSESSMENT 
OF ANTIMICROBIAL EFFICACY 
Before the use of current antimicrobials can be 
optimized, a satisfactory way to assess their efficacy 
must be found. Antimicrobials are usually assessed 
formally in clinical trials, and prescribing recommen- 
dations are often made based on these trials. Although 
clinical trials constitute the accepted way of proving the 
therapeutic efficacy of antimicrobials, their limitations 
must always be borne in mind, in order to avoid reach- 
ing unsupported conclusions. 
Study design and sample size are problems in many 
clinical trials. Trials of new agents in comparison to the 
established therapy are often designed to show non- 
inferiority only, rather than superiority. This is because 
more than 700 patients are needed in each of the two 
arms of the trial in order to show that one agent has a 
clinical success rate that is 5% better than another 
agent. In practice, this number of patients is difficult to 
obtain in many clinical trials, and their statistical power, 
therefore, tends to be weak. Data from small clinical 
trials must always be interpreted carefully. Furthermore, 
statistically similar outcomes between two antimicro- 
bials in a trial that was designed to show non-inferiority 
do not mean that the two agents tested have equivalent 
efficacy-only that the study was not powered to show 
any difference in efficacy. 
The primary problem with clinical trials is that most 
do not assess antimicrobial efficacy, i.e. the ability of 
the antimicrobial to eradicate the bacterial infection. 
Instead, clinical trials generally assess only clinical cure. 
Data on bacteriologic outcome, if determined, are usually 
only available from a small number of patients, and the 
number of antimicrobial-resistant bacterial isolates 
is often too low to allow the assessment of efficacy. 
In addition, if included, bacteriologic outcomes may 
actually be ‘presumed bacteriologic success or failure’; 
that is, the patient had a bacterial pathogen isolated 
at baseline, and was a clinical cure, or failure, in the 
absence of a follow-up microbiologically evaluable 
sample. Another limitation is that, in most trials, patients 
are enrolled based on a clinical diagnosis, and in the case 
of respiratory tract infections, patients who do not have 
a bacterial infection will almost certainly be included. 
The importance of bacteriologic evaluation in clinical 
trials cannot be overemphasized. 
The perceived value of the clinical assessment of 
antimicrobials is perpetuated in clinical guidelines. 
For example, neither the Infectious Diseases Society 
of America2 nor the American Thoracic Society3 
guidelines for the management of community-acquired 
pneumonia indicate that sputum culture is required for 
outpatients, while both recommend clinical response as 
a measure of the efficacy of the empirical antimicrobial 
chosen. 
Although clinical assessment may seem to be more 
practical than bacteriologic evaluation, on its own it may 
result in a false interpretation of therapeutic success. 
Marchant et al reviewed the results of randomized, 
double-blind trials of antimicrobials in acute otitis 
media to determine bacteriologic and associated clinical 
success rates.4 They found that, for a drug with a 
bacteriologic efficacy of lOO%, the calculated clinical 
efficacy was 93% for acute bacterial otitis media, and for 
a drug with a bacteriologic efficacy of 27% (equivalent 
to spontaneous resolution with no antimicrobial therapy), 
the calculated clinical efficacy was 71%. Thus, an agent 
that has little antimicrobial activity will appear to be 
reasonably effective if only clinical criteria are used 
(Figure 2). The authors of this study named this the 
‘Pollyanna phenomenon’, after the over-optimistic 
heroine of the eponymous novel. 
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Figure 2. Success of antimicrobial treatment for acute 
bacterial otitis media based on bacteriologic and clinical 
criteria. Redrawn with permission from Marchant et al.4 
THE GOALS OF ANTIMICROBIAL THERAPY 
The primary goal of antimicrobial therapy should be 
bacterial eradication. Antimicrobials that maximize 
bacterial eradication will also maximize clinical cures 
(see J. Garau, this issue). The direct association of 
bacteriologic success and clinical success has been 
clearly shown by Dagan et a1.‘jT7 In their series of 123 
patients with acute otitis media,6 a high clinical success 
rate (97%) was achieved in those whose middle ear fluid 
was culture negative on day 4-5 after starting anti- 
microbial treatment. In contrast, the clinical success 
rate was only two-thirds of this (63%) in those children 
whose middle ear fluid was culture positive. A significant 
association between high bacterial eradication and high 
clinical cure has also been demonstrated in acute 
exacerbations of chronic bronchitis.8 
Bacteriologic success is also critical to prevent the 
emergence of resistance (see J. Garau, this issue). For 
example, Dabernat et al found that, in nasopharyngeal 
samples from children with acute otitis media treated 
with cefixime or amoxicillin-clavulanate, the proportion 
of S. pneumoniae strains resistant to penicillin was 
higher at the end of treatment (56.0%, 65/116 S. pneu- 
moniae strains) and at follow-up (50.3%, 69/137) than 
at inclusion (38.8%) 87/224).9 Cefixime did not decrease 
penicillin-resistant S. pneumoniae carriage after treatment, 
whereas amoxicillin-clavulanate significantly decreased 
the carriage of these strains, with only 17/42 patients still 
carrying penicillin-resistant S. pneumoniae after therapy 
(Figure 3).9 
The WHO acknowledges the evidence supporting 
bacterial eradication, issuing the following statement in 
2000: ‘The most effective strategy against antimicrobial 
resistance is to get the job done right the first time-to 
unequivocally destroy microbes-thereby defeating 
resistance before it starts.‘lO In other words, the old 
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Figure 3. Nasopharyngeal carriage of penicillin-susceptible 
and penicillin-resistant 5. pneumoniae before and after 
treatment with amoxicillin-clavulanate or cefixime. Data 
obtained from Dabernat et aLg 
philosophy of saving the best agents for last is wrong, 
and the most effective antimicrobials should be used 
from the start to eradicate all bacterial pathogens and 
thus minimize the selection of resistant strains. 
PREDICTING BACTERIAL ERADICATION 
If bacterial eradication is the primary goal of anti- 
microbial therapy, and clinical trials cannot provide us 
with the data to determine which agents will achieve 
this goal, how do we proceed towards appropriate 
prescribing? Studies in both animals and humans 
indicate that the relationship between pharmacokinetics 
and pharmacodynamics (PK/PD) can be used to predict 
antimicrobial bacteriologic efficacy (see M. R. Jacobs, 
this issue). 
Antimicrobials cause either time-dependent killing 
(e.g. penicillins, cephalosporins, and most macrolides) or 
concentration-dependent killing (e.g. azalides and 
fluoroquinolones). For agents causing time-dependent 
killing, the PK/PD parameter predictive of bacterial 
eradication is the duration of the dosing interval for 
which antimicrobial concentrations at the site of in- 
fection exceed the MIC of the infecting pathogen, 
or time above MIC (T > MIC). Mortality in animal 
models infected with S. pneumoniae is minimized when 
the T > MIC is 25-40% for penicillins and 40-50% for 
cephalosporins. r1,12 For agents, such as the fluoroquino- 
lanes, with concentration-dependent killing, the ratio 
of the area under the concentration-time curve (AUC) 
and the MIC, or the ratio of the maximum plasma 
concentration (CL,,) and the MIC, are predictive of 
bacterial eradication.rr-l3 For fluoroquinolones, an 
AUC/MIC ratio of 25 is predictive of bacterial eradica- 
tion for S. pneumoniae, although ratios of >125 are 
required to eradicate Gram-negative pathogens, or in 
immunocompromised patients.11,13 
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Pharmacodynamic parameters can also be used 
to predict the potential of an antimicrobial to select 
resistant strains during therapy. Based on the results of 
four treatment trials in patients with lower respiratory 
tract infections treated with fluoroquinolones, Thomas 
et al calculated that if the AUCYMIC ratio was 100 
or higher, only 9.3% of organisms would develop 
resistance, whereas if the AUC/MIC ratio was less than 
100,82.4% of strains would develop resistance.iJ 
The assessment and choice of antimicrobials, the 
development of new agents and the optimization of 
currently available agents, should, therefore, be directed 
by PK/PD predictions of bacterial eradication (see 
R. Dagan, this issue). By setting a PK/PD target that 
predicts bacteriologic efficacy against resistant pathogens, 
doses and regimens can be developed that extend the 
activity of current agents against these strains. Thus, 
antimicrobials that can be optimized can continue to 
provide bacteriologically effective therapy for respira- 
tory tract infections, even in regions where resistance 
prevalences are high. 
CONCLUSIONS 
The continued development and spread of resistance 
in bacterial respiratory tract pathogens represents a 
challenge to clinical therapy that has to be met with an 
evidence-based approach (see K. Klugman, this issue). 
The relationship between antimicrobial prescribing 
in respiratory tract infections, bacterial resistance and 
clinical outcomes is complex. However, it is becoming 
clear that the old prescribing paradigm of ‘save the best 
until last’ needs to be revised. It is vital to break the 
vicious cycle of antimicrobial resistance. If antimicrobial 
treatment choice and dose are not appropriate, not all of 
the bacterial pathogens will be eradicated, and resistant 
strains will be selected. These resistant strains will 
spread, the overall prevalence of resistance will increase, 
possibly compromising future antimicrobial therapy, and 
the cycle will begin again. To break this vicious cycle, the 
antimicrobial treatment should be appropriate, i.e. the 
right choice and dose to achieve bacterial eradication, 
thereby maximizing clinical cure and minimizing the 
emergence of resistance. 
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